Xin Lang Cai Jing·2025-11-06 01:27Core Viewpoint - Junshi Biosciences experienced a slight decline in stock price, with significant trading activity in both margin financing and securities lending, indicating high investor interest and potential volatility in the stock [1][2]. Financing Summary - On November 5, Junshi Biosciences had a financing buy-in amount of 39.95 million yuan, with a net buy of 572,900 yuan after repayments [1]. - The total margin financing and securities lending balance reached 1.404 billion yuan, with the financing balance accounting for 4.68% of the circulating market value, indicating a high level of leverage compared to the past year [1]. - The company’s financing balance of 1.391 billion yuan is above the 90th percentile of the past year, suggesting strong investor confidence [1]. Securities Lending Summary - On the same day, Junshi Biosciences repaid 4,500 shares in securities lending while selling 600 shares, with a total selling amount of 23,300 yuan based on the closing price [1]. - The remaining securities lending balance was 32,710 shares, with a total value of 12.697 million yuan, also exceeding the 90th percentile of the past year [1]. Company Overview - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% increase in losses [2]. - The number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2].